

Heparosan as a potential alternative to hyaluronic acid for the design of biopolymer-based nanovectors for anticancer therapy

Marlène Rippe, Talitha F. Stefanello, Vanessa Kaplum, Elizandra A. Britta, Francielle P. Garcia, Robin Poirot, Mychelle V. P. Companhoni, Celso V. Nakamura, Anna Szarpak-Jankowska, Rachel Auzély-Velty *




Figure S1. (A) Kinetic plots and (B) dependence of the number-average molar masses (M_n) on monomer conversion for the RAFT copolymerization of DEGMA and BMA. Reaction conditions: $[\text{DEGMA}]_0/[\text{BMA}]_0/[\text{CTA}]_0/[\text{AIBN}]_0 = 95/5/0.77/0.038$ at 80°C in toluene.




Figure S2. Characterisation of poly(DEGMA-co-BMA) by A) ¹H NMR spectroscopy (300 MHz, 10 mg/mL in CDCl₃ and, B) SEC at 30 °C and at a flow rate of 1 mL/min, in dimethylformamide containing 50 mM NaNO₃.




Figure S3. Turbidity measurement of a solution of poly(DEGMA-co-BMA) in PBS (0.5 g/L) as measured by UV/Vis spectroscopy at 500 nm.




Figure S4. FT-IR spectra of crosslinked Hep-NGs with $[\text{SH}]/[=] = 2$ (blue) and $[\text{SH}]/[=] = 1$ (purple), and of un-crosslinked Hep-NGs (orange). Focus on the 1800-400 cm^{-1} region includes characteristic bands of DTT on the heparosan backbone.




Figure S5. Behavior as a function of temperature of nanogels based on Hep-p-poly(DEGMA-co-BMA) and HA-p-poly(DEGMA-co-BMA) crosslinked with a [SH]/[=] ratio of 1. Analysis by DLS ($C_p = 0.5$ g/L in PBS) and by SEM of Hep NGs (A, B, C) and of HA NGs (D, E, F).




Figure S6. *In vitro* cytotoxicity of un-crosslinked and crosslinked HA- and Hep-NGs as well as of native HA and Hep in Vero cells after 72 h of incubation, evaluated by the MTT method. Data are expressed as mean \pm SD of three independent experiments.




Figure S7. Size distribution of shell-crosslinked HA NGs (A) and Hep NGs (B) in PBS ($C_p = 5 \times 10^{-4}$ g/L) determined by nanoparticle tracking analysis at 25 °C. The experimental results (black curve) were fitted by a Gaussian curve (red curve).




Figure S8. Quantification of the *ex vivo* biodistribution of Cy7-labeled initial HA40 and Hep30 in normal mice 24 h after administration (n = 3/organ). The results in each organ are expressed as the mean of relative light unit \pm SD (n=3).